Polarean Imaging Plc operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The company is headquartered in Durham, North Carolina and currently employs 26 full-time employees. The company went IPO on 2018-03-29. The firm and its subsidiary company, Polarean, Inc., operate as investigational drug-device combination companies operating in the high-resolution medical imaging research space. The firm has developed the hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW (xenon Xe 129 hyperpolarized). The company develops equipment that enables existing MRI systems to achieve an improved level of pulmonary functional imaging. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream. Its technology provides an investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform.
Follow-Up Questions
Polarean Imaging PLC のCEOは誰ですか？
Dr. Christopher Von Jako は Polarean Imaging PLC の Chief Executive Officer で、2023 から在籍しています。
PLLWF の株価パフォーマンスは？
PLLWF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Polarean Imaging PLC の主な事業テーマや業界は？
Polarean Imaging PLC は Health Care 業界、セクターは Health Care に属しています。
